Takeaway
Regional tau PET and cortical thickness correlated with cognitive behaviour in clinical stages of Alzheimer’s Disease (AD), and tau PET was more sensitive than β-amyloid (Aβ) PET for detecting early cognitive changes in preclinical AD.
Why this matters ?
Identifying how neurobiological hallmarks of AD contribute to cognitive changes could improve the diagnostic and prognostic process in AD and trial design.